News

Hecht Foundation / Canadian Cancer Society Competition: Disruptive Innovation in Cancer Research

This funding opportunity is provided by the Lotte and John Hecht Memorial Foundation in collaboration with the Canadian Cancer Society. It is designed to spark innovation which may be of benefit to the field of cancer research. The competition is not looking for typical projects which may be likely to get funding through typical funding pathways, but rather to find innovative, out-of-the-box intuitive or discovery-inspired projects which would be otherwise unlikely to be successful in securing funding via traditional competitions.

Report worth reading: Situational analysis of BC’s clinical trials ecosystem

Clinical trials play an important role in discoveries making it through the translational medicine pipeline. Health Research BC has released a report that critically examines how the clinical trial ecosystem in British Columbia compares to other provinces. The report sheds light on the strengths that BC has, as well as its challenges, and suggests future directions accordingly. Click the link to access a summary as well as a link to the full document.

V Foundation Translational Grant

The V Foundation is offering a 4-year grant of $800,000 grant ($200,000 per year) for translational research in the broad area of adult cancers, targeted towards those in their mid-to-senior-career. Those interested must apply soon, as UBC's internal deadline is 28 February 2025.

Lab2Market – Validate Foundations

The Lab2Market program has announced a free 3-day virtual opportunity in late March 2024, Validate Foundations, aimed at physicians who contribute to health innovation. Clinician scientists who are researching emerging technologies may find this program relevant. The application deadline is 17 March 2025.

Grant Call: Rapid Response 2025 Program

The Rapid Response Program provides seed funding to catalyze novel, high-risk, high-reward translational research that accelerates the development of therapeutics or tools for neurodegenerative diseases of aging. This is a great opportunity for those in the ATM's community who are actively working to propel such research forward.